预约演示

Stefan Fraenkel takes over as chief of Inceptua Group; Christi Shaw has a plan to make Yescarta safer

2019-12-11

高管变更

Stefan Fraenkel Inceptua → After its subsidiary Inceptua Medicines Access inked a deal with Onconova Therapeutics to make available intravenous rigosertib via a pre-approval access program in selected countries across the world, Inceptua Group has tapped Stefan Fraenkel to head the company’s operations as CEO. Fraenkel, currently EVP of the company’s business unit Inceptua Pharma, will succeed Alan Raffensperger — who is moving to the position of executive vice-chairman of the group. Fraenkel joined the company in 2017 and holds experience from his previous roles at Wyeth Pharmaceuticals and Sobi. → Christi Shaw has identified Kiniksa and its mavrilimumab as a combination agent that can potentially make Kite’s Yescarta safer. Shaw, who was appointed as the Gilead subsidiary’s CEO a few months ago, agreed to sponsor a Phase II study on relapsed or refractory large B-cell lymphoma and shoulder all the work. Kiniksa obtained the drug — which inhibits the granulocyte macrophage colony-stimulating factor receptor alpha (GM-CSFRα) — from AstraZeneca last year during the pharma giant’s divestiture spree. → CRISPR, the keenly watched gene-editing tool often likened to pair of molecular scissors, offers great promise to treat disease, but the danger of off-target effects loom large. Gene editing company Editas Medicine — whose chief Katrine Bosley announced her surprising exit in January — has tied up with California-based GenEdit, a company that has developed a platform for non-viral- and non-lipid-based delivery of gene therapies, in an effort to improve safety and efficiency. → Oxford, UK-based research company Arctoris — which closed a seed funding round of £3.2 million back in September — has opened the doors to its new headquarters and R&D facility in Oxford.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构